Major Depressive Disorder
A serious mental health condition marked by at least two weeks of pervasive sadness and loss of interest, impairing daily life and requiring medical and psychological treatment.
Emergency Management: Active suicidal ideation with a plan requires immediate psychiatric emergency evaluation, potentially involving involuntary admission to a psychiatric facility to ensure patient safety.
Major Depressive Disorder (MDD) is a common but serious mood disorder characterized by a persistent feeling of sadness, profound loss of interest in activities (anhedonia), and a range of neurovegetative symptoms that significantly impair daily functioning. It is not merely 'feeling sad,' but a complex biological and psychological illness.
Detailed Overview
MDD episodes must last for at least two consecutive weeks. It has profound impacts on sleep, appetite, energy, and cognition, often accompanied by feelings of worthlessness and suicidal ideation. Pathophysiologically, it involves dysregulation of monoamine neurotransmitters and structural changes in the hippocampus and prefrontal cortex. Management requires a combination of pharmacotherapy, psychotherapy, and in severe cases, neurostimulation.
Epidemiology & Demographics
Lifetime prevalence in the US is approximately 20%. It is roughly twice as common in females as in males. The peak onset is in the 20s, though it can occur at any age.
Etiological Mechanism
Multifactorial. Involves genetic vulnerability (heritability is ~35%), severe life stress or trauma (epigenetic changes), and neurobiological abnormalities.
Primary Causes
No single cause. Triggered by a combination of genetic predisposition, biochemical imbalances (serotonin, norepinephrine, dopamine depletion), and psychosocial stressors (loss, trauma).
The traditional Monoamine Hypothesis posits a deficiency in serotonin, norepinephrine, and dopamine. The Neurotrophic Hypothesis suggests stress-induced decreases in Brain-Derived Neurotrophic Factor (BDNF) lead to neuronal atrophy and decreased neurogenesis in the hippocampus and prefrontal cortex. Hyperactivity of the Hypothalamic-Pituitary-Adrenal (HPA) axis, leading to chronically elevated cortisol, also drives these neurotoxic structural brain changes and systemic inflammation.
Diagnostic Criteria & Guidelines
DSM-5 Criteria: 5 or more of the following 9 symptoms present during the same 2-week period; at least one symptom must be depressed mood or anhedonia. Symptoms: 1. Depressed mood, 2. Anhedonia, 3. Weight/appetite change, 4. Sleep disturbance, 5. Psychomotor agitation/retardation, 6. Fatigue, 7. Feelings of worthlessness/guilt, 8. Diminished concentration, 9. Suicidal ideation. (Mnemonic: SIGECAPS).
Selective Serotonin Reuptake Inhibitors (SSRIs) e.g., Escitalopram 10 mg PO daily, Fluoxetine 20 mg PO daily, or Sertraline 50 mg PO daily. PLUS Evidence-based psychotherapy, specifically Cognitive Behavioral Therapy (CBT) or Interpersonal Therapy (IPT).
Second-Line & Adjunctive Therapy
If SSRI fails, switch to an SNRI (e.g., Venlafaxine 75-150 mg PO daily) or an atypical antidepressant (e.g., Bupropion 150 mg PO XL daily, especially useful for fatigue/anhedonia without sexual side effects). Augmentation with Aripiprazole 2-5 mg/day.
Surgical & Procedural Management
Electroconvulsive Therapy (ECT) is highly effective for treatment-resistant depression, severe suicidality, or depression with psychotic features.
Patient Counseling & Advice
Educate that antidepressants take 4 to 6 weeks to show full effect, and side effects (nausea, jitteriness) often precede clinical benefit. Emphasize that depression is a medical illness, not a character flaw.
Follow-Up & Monitoring Schedule
Monitor weekly to bi-weekly upon initiating medication to assess for increased suicidality (especially in young adults < 25), tolerability, and early clinical response. Assess severity using PHQ-9.
Preventive Strategies
Maintenance therapy with an antidepressant for at least 6-12 months after the first episode, and indefinitely for patients with 3 or more episodes.
Highly treatable. 50% recover within 6 months. However, the recurrence rate is high; ~50% of patients will have a second episode, and those with two episodes have an 80% chance of a third.